Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series Ltd: World’s leading Event Organizer
(10 Plenary Forums - 1Event)
Chicago, Illinois, USA
As per available reports about 6 Relevant journals, 108 Conference proceedings are presently dedicated exclusively to Osteoporosis Medicine and about 110 Open access articles , 45 National symposiums are being published on Osteoporosis Medicine.
Osteoporosis medicine is used in the treatment of osteoporosis. Osteoporosis is characterised by thinning of the bones, with reduction in bone mass, due to depletion of calcium and bone protein. Osteoporosis leads to fractures, which are often slow to heal. It is most common in older adults, particularly postmenopausal women, and in patients who take steroids or steroidal drugs. Treatment of osteoporosis includes exercise ensuring that the diet contains adequate calcium and other minerals needed to increase new bone growth, use of medications to improve bone density, and sometimes for postmenopausal women, use of hormone therapy.
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Scope and Importance:
Osteoporosis is characterized by decreased bone mineral density (BMD), which causes brittle bones and increases the risk of fracture. The disease affects 10 million americans, with 34 million more estimated to have a low bone mass and increased risk of the disease. With increase in age bone mineral density naturally decreases, osteoporosis most commonly affects those above the age of 50.Osteoporosis Conference provides a wide range of learning opportunities progressed by international and national experts. Osteoporosis Conference offers excessive quality content to suit the diverse professional development needs of high acuity and critical care nurses. Osteoporosis Conference is a perfect platform to discuss the novel techniques and it also provides the chance for the attendees to present and discuss the most recent innovations, trends, and the solutions adopted Osteoporosis treatment.
Osteoporosis conference aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results about all aspects of:
2. Carpal Tunnel Syndrome
3. Dupuytren’s Contracture
It also provides the platform for researchers, scholars and educators to present and discuss the most recent innovations, trends, and concerns, practical challenges encountered and the solutions adopted in the field of Arthritis.
Osteoporosis is a silent disease. You might not know you have it until you break a bone. A bone mineral density test is the best way to check your bone health. To keep bones strong, eat a diet rich in calcium and vitamin D, exercise and do not smoke. If needed, medicines can also help. A few pharmaceuticals moderate the rate of bone misfortune or expand bone thickness. Indeed little measures of new bone development can lessen your danger of broken bones. Osteoporosis makes your bones weak and more likely to break. Anyone can develop osteoporosis, but it is common in older women. As many as half of all women and a quarter of men older than 50 will break a bone due to osteoporosis.
There are two categories of Osteoporosis medications: antiresorptive medications that slow bone loss and anabolic drugs that increase the rate of bone formation. Bone Remodeling Cycle: Bone is living, growing tissue that constantly forms new bone while replacing older bone. Bone continuously renews and changes through a process called remodeling. The bone remodeling cycle consists of two distinct stages: bone resorption (breakdown or removal) and (2) bone formation. During resorption, special cells (osteoclasts) on the bone's surface dissolve bone tissue and create small cavities. During formation, other cells (osteoblasts) fill the cavities with new bone tissue.
Usually, bone resorption and bone formation take place in close sequence and remain balanced. An imbalance in the bone remodeling cycle occurs with menopause and with aging in both genders, and it can occur with other conditions. An imbalance can result in bone loss that eventually leads to osteoporosis and broken bones (also called fractures). Antiresorptive Medications: Bisphosphonates, calcitonin, denosumab, estrogen and estrogen agonists/antagonists are antiresorptive medicines. They slow the bone loss that occurs in the breakdown part of the remodeling cycle. When people first start taking these medicines, they stop losing bone as quickly as before, but still make new bone at the same pace. Therefore, bone density may increase. The goal of treatment with antiresorptive medicines is to prevent bone loss and lower the risk of breaking bones.
Anabolic Drugs: Teriparatide, a form of parathyroid hormone, increases the rate of bone formation and is in a distinct category of osteoporosis medicines called anabolic drugs. This is currently the only osteoporosis medicine approved by the FDA that rebuilds bone. The goal of treatment with teriparatide is to build bone and lower the risk of breaking bones.
Creighton University Osteoporosis Research Center (ORC) continues today a 40-year effort that has created an international center of excellence in bone research. This team carries out: patient care, including state-of-the-art evaluation, diagnosis, and treatment basic-science research, which is laboratory-based basic-science research, which is laboratory-based The ORC team includes nearly 50 persons: A distinguished faculty - including physician-scientists, molecular biologists, molecular geneticists, nurse-scientists, a computer scientist, a statistician, an exercise physiologist, and a biomechanical engineer - whose work is recorded in an impressive list of recent publications.
A skillful staff, including research nurses, a research dietitian, an information technology specialist, laboratory technicians, bone densitometry technicians, research assistants, administrative staff; and Professional, graduate, and post-doctoral students. The activities of the ORC are organized into Departments, which provide professional, technical, and support services. How Long to Treat: There are currently no conclusive research findings to suggest how long an osteoporosis drug remains safe and effective, except for teriparatide (Forteo®). Teriparatide can be taken for no more than two years according to the FDA. It is uncertain how long any of the osteoporosis medicines remain effective after they are stopped.
Past Experience and Studies: Past experience with bisphosphonates (Actonel®, Boniva® and Fosamax®) suggests that upon discontinuation of any of these drugs, the benefits may continue for several years or longer. This is because the drugs remain in the bone for a long time. Eventually, however, the beneficial effect begins to lessen, bone remodeling rates increase and bone loss may occur.
One study found that alendronate (Fosamax®) continued to have a beneficial effect on bone mineral density for up to 10 years in postmenopausal women taking the medicine. Biopsies of bone tissue in women on alendronate for 10 years show that bone tissue looks healthy and normal. Other studies show that treating with alendronate for more than five years improves bone strength and reduces fractures of the spine.
The Osteoporosis medicine market is divided into four regions: North America, Asia- Pacific, Europe and Rest of the World (ROW). The North American region holds the major place in the world osteoporosis drug market. Americans with 34 million were estimated to have a low bone mass and increased risk of the disease. Among all the drug classes the global osteoporosis drugs market is dominated by bisphosphonates segment accounting for a market share of 48.2% in 2013. The global osteoporosis drugs market was valued at USD 8.4 billion in 2013 and is estimated to reach a market worth of $8.9 billion in 2020 growing at a CAGR of 1.2% from 2014 to 2020. An estimated $18 billion is spent annually on direct health care services related to osteoporotic fractures.
4. Internal Medicine Conference
November 03-05, 2016 Baltimore, Maryland, USA
5. Healthcare Conference
October 05-07, 2015 New Delhi, India
7. Musculoskeletal Regeneration Conference
May 05-06, 2016 Chicago, USA
8. Biomaterials Conference
March 14-16, 2016 London, UK
10. Novel Physiotherapies Conference
October 20-22, 2016 Kuala Lumpur, Malaysia
16. ICOR 2016: 18th International Conference on Orthopedics and Rheumatology
March 1 - 2, 2016, Miami, USA
17. The Shoulder – Internationale Konferenz Shoulder Revision Arthroplasty 2016
January 15-16, 2016, Hambourg, Germany
18. Oswestry Intensive Course in Basic Science in Orthopaedics 2016
January 10-15, 2016, Oswestry, United Kingdom
19. Freiburger Knorpeltage 2016 – Fribourg Cartilage 2016
February 19-20, 2016, Freiburg, Germany
20. 36th Overseas Orthopaedic Meeting and 3° Indian Ocean Spine Meeting
March 26- April 02, 2016, Saint Gilles Ile de la Réunion, France.
21. Osteoarthritis Research Society International (OARSI) 2016 World Congress
March 31 - April 3, 2016 - Amsterdam, Netherlands
Relevant Society and Associations
1. National Osteoporosis Medicine
2. National Osteoporosis Society
3. International Osteoporosis Foundation
4. The European Society for Clinical and Economics Aspects of Osteoporosis and
5. Bulgarian Medical Society of Osteoporosis and Osteoarthritis
6. Japan Osteoporosis Society
7. Turkish Osteoporosis Society
8. Irish Osteoporosis Society
9. British Osteoporosis Society
10. Pan Arab Osteoporosis Society
11. Polish Osteoarthrology Society
12. Syrian National Osteoporosis Society (SYNOS)
13. Argentine Society of Osteoporosis (SAO)
14. Croatian Osteoporosis Society
15. Osteoporosis Society of India
16. Swedish Osteoporosis Society
17. The Arthritis Society
18. American Arthritis Society
19. Canadian Arthritis Society
20. National Rheumatoid Arthritis Society
1. Zelos Therapeutics Inc
2. Velcura Therapeutics, Inc
3. Osteometer MediTech, Inc
4. Amura Therapeutics Ltd
5. Actavis plc,
6. Amgen, Inc.,
7. DJO Global
11. Microchips Biotech Inc
12. Vilex, Inc
13. Azelon Pharmaceuticals, Inc
14. TransPharma Medical Ltd.
15. Eli Lilly and Company,
16. F.Hoffmann La Roche Ltd.
17. Novartis International AG,
18. Novo Nordisk A/s
19. Pfizer, Inc.,
20. Teva Pharmaceutical Industries Ltd.
This page will be updated regularly.
This page was last updated on 18th Sep, 2015
1-702-508-5200 Ext:8031, 8041
1-702-508-5200 Ext:8045, 8047
Immunology & Microbiology Conferences
Nursing and Healthcare Conferences
Clinical and Biochemistry Conferences
1-702-508-5200 Ext:8031, 8037
Material Science Conferences
Genetics & Mol Biology Conferences
Media Partners | Advertising